The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index; 1 of the 19 sources its claims cite were checked for support.
Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program
Open accessAbstract
Insulin resistance and beta-cell dysfunction, two factors central to the pathogenesis of type 2 diabetes, were studied in relation to the development of diabetes in a group of participants with impaired glucose tolerance in the Diabetes Prevention Program (DPP) at baseline and after specific interventions designed to prevent diabetes. Participants were randomly assigned to placebo (n = 1,082), metformin (850 mg twice a day) (n = 1,073), or intensive lifestyle intervention (n = 1,079). The diabetes hazard rate was negatively associated with baseline insulin sensitivity (hazard rate ratio = 0.62-0.94 per SD difference, depending on treatment group and measure of sensitivity) and with baseline insulin secretion (hazard rate ratio = 0.57-0.76 per SD). Improvements in insulin secretion and insulin sensitivity were associated with lower hazard rates in all treatment arms (hazard rate ratio = 0.46-0.95 per SD increase and 0.29-0.79 per SD increase, respectively). In multivariate models that included the three metabolic variables (changes in body weight, insulin sensitivity, and insulin secretion) each significantly and independently predicted progression to diabetes when adjusted for the other two variables. The intensive lifestyle intervention, which elicited the greatest reduction in diabetes incidence, produced the greatest improvement in insulin sensitivity and the best preservation of beta-cell function after 1 year, whereas the placebo group, which had the highest diabetes incidence, had no significant change in insulin sensitivity and beta-cell function after 1 year. In the metformin group, diabetes risk, insulin sensitivity, and beta-cell function at 1 year were intermediate between those in the intensive lifestyle and placebo groups. In conclusion, higher insulin secretion and sensitivity at baseline and improvements in response to treatment were associated with lower diabetes risk in the DPP. The better preventive effectiveness of intensive lifestyle may be due to improved insulin sensitivity concomitant with preservation of beta-cell function.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
59 Own result · 15 Own interpretation · 10 No full text of the sources · 4 No basis given · 2 Own method · 1 Partly supported · 1 Sources not found · 1 Not checked yet · accuracy not yet measured
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Correlations between the year 1 changes in metabolic variables were similar among the treatment groups, except for the correlations between 1/fasting insulin and either CIR or IGR, which were higher in the metformin group.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Improvements in insulin secretion and insulin sensitivity were associated with lower hazard rates in all treatment arms (hazard rate ratio ؍ 0.46 -0.95 per SD increase and 0.29 -0.79 per SD increase, respectively).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard rates for developing diabetes were positively associated with baseline fasting plasma glucose, 120-min plasma glucose, and A1C (Fig. 3).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Prediction of diabetes by individual metabolic factors
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this large cohort of individuals with IGT, our results clearly confirm this relationship because each variable had an independent effect on the risk of developing diabetes.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Fasting and 30-and 120-min glucose values decreased significantly in the lifestyle group”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“this change was relatively less than the change in insulin sensitivity”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“whereas the placebo group, which had the highest diabetes incidence, had no significant change in insulin sensitivity and -cell function after 1 year.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“and with baseline insulin secretion (hazard rate ratio ؍ 0.57-0.76per SD).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the lifestyle and placebo groups, hazard rates were negatively associated with baseline 1/fasting insulin.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Baseline and changes in body weight, insulin sensitivity, and insulin secretion.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The hazard rates for diabetes were positively associated with baseline weight in the lifestyle and placebo groups when adjusted for baseline demographics (age, sex, and race/ethnicity) (Fig. 4, left panels).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Baseline and changes in body weight, insulin sensitivity, and insulin secretion.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- The authors state this as an assumption: Hazard ratios were constant over time.
- It may state two separate claims as one. 24
- Probably not a substantial claim. 7
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The latter two are strong risk factors for type 2 diabetes (1-6).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
What the sources say
- Not checked — no full text of the sourcecites [1] The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403,2002 source
- Partly supportedcites [2] Modan M, Karasik A, Halkin H, Fuchs Z, Lusky A, Shitrit A, Modan B: Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non-insulin-dependent) diabetes and on insulin response: the Israel study of glucose intolerance, obesity and hypertension. Diabetologia 29:82–89,1986 sourceExperimental — accuracy not yet measured
The BMI INTERVAL section describes impaired glucose tolerance progressing to Type 2 diabetes, and the Discussion likewise describes worsening from impaired tolerance to diabetes. But the paper does not address impaired fasting glycemia or establish that both conditions are strong risk factors. Page numbers are unavailable in our copy. (LLM, conf=0.84)
- Not checked — no full text of the sourcecites [3] Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH: The natural history of impaired glucose tolerance in the Pima Indians. N Engl J Med 319:1500–1506,1988 source
- Not checked — no full text of the sourcecites [4] Lillioja S, Mott DM, Howard BV, Bennett PH, Yki-Jarvinen H, Freymond D, Nyomba BL, Zurlo F, Swinburn B, Bogardus C: Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 318:1217–1225,1988 source
- Not checked — no full text of the sourcecites [5] Edelstein SL, Knowler WC, Bain RP, Andres R, Barrett-Connor EL, Dowse GK, Haffner SM, Pettitt DJ, Sorkin JD, Muller DC, Collins VR, Hamman RF: Predictors of progression from impaired glucose tolerance to NIDDM: an analysis of six prospective studies. Diabetes 46:701–710,1997 source
- Not checked — no full text of the sourcecites [6] Jensen CC, Cnop M, Hull RL, Fujimoto WY, Kahn SE, American Diabetes Association GENNID Study Group: β-Cell function is the major determinant of oral glucose tolerance in four ethnic groups in the United States. Diabetes 51:2170–2178,2002 source
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“At 1 year, there was less reduction in fasting insulin in the metformin than in the lifestyle group, with the lifestyle participants having the greatest reduction throughout all years of follow-up.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ISI and 1/fasting insulin were, as expected, highly correlated at baseline (Spearman r ϭ 0.99).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > July 2001 (see DATA ANALYSIS).
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Encompassing of the additional follow-up data yielded risk reductions (95% CI) of developing diabetes of 30% (16 -41%) for metformin and 55% (45-63%) for lifestyle, each compared with placebo.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > July 2001 (see DATA ANALYSIS).
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, we found that A1C, proinsulin, insulin sensitivity, and insulin secretion also predicted the development of diabetes in these high-risk individuals.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among all participants, including those who developed diabetes, fasting glucose, insulin, and proinsulin concentrations were significantly lower than placebo at the first annual visit in the metformin and the lifestyle groups and increased during the 2nd and 3rd years, with the levels remaining significantly lower than in the placebo group (Fig. 2).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In the placebo group, however, there was a significant increase in 30-min and a significant decrease in the 120-min glucose levels.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in metabolic variables over time.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Whereas lifestyle and metformin treatments reduced the incidence of diabetes, they did not change the independent effects of insulin sensitivity and secretion on the risk for diabetes, so that those individuals with the lowest sensitivity and secretion within each treatment group still had the greatest risk, whereas those with the highest insulin sensitivity and secretion had uniformly low risk”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Changes in weight and proinsulin over time were strong predictors of diabetes, with decreased weight and decreased proinsulin predicting a lower hazard of diabetes in all treatment arms (Fig. 4B and D).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Baseline and changes in body weight, insulin sensitivity, and insulin secretion.
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- The authors state this as an assumption: Hazard ratios were constant over time.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The metformin group showed a more modest improvement in insulin sensitivity (ISI and 1/fasting insulin, P Ͻ 0.001) with a significant decrease in insulin secretion (IGR, P Ͻ 0.001)”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in insulin secretion and sensitivity.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In addition, improved insulin sensitivity was also associated with a decrease in the risk of developing diabetes, with the lifestyle intervention again being the most effective.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, in the placebo group there were no significant changes in either estimate of insulin sensitivity, a significant decrease in insulin secretion (IGR, P ϭ 0.03) but no significant change in -cell function”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in insulin secretion and sensitivity.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The intensive lifestyle intervention, which elicited the greatest reduction in diabetes incidence, produced the greatest improvement in insulin sensitivity and the best preservation of -cell function after 1 year”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The lifestyle group had the greatest improvement in insulin sensitivity (ISI and 1/fasting insulin, P Ͻ 0.001), and this was associated with a significant decrease in insulin secretion (IGR, P ϭ 0.008).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in insulin secretion and sensitivity.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The relationships in the current data were not hyperbolic but were well described as nonlinear.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
boostedcorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The risk of developing diabetes was lowest among participants in the lifestyle arm, intermediate among those assigned to metformin, and highest among placebo participants across the range of baseline glycemic variables.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Prediction of diabetes by individual metabolic factors
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In general, these treatment effects were seen regardless of the categories of sensitivity and secretion, except in the lowest risk categories (high insulin sensitivity and secretion), in which hazard rates were uniformly low.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Prediction of diabetes by multiple metabolic factors Baseline insulin sensitivity and insulin secretion.
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“found that the risk for developing type 2 diabetes was reduced by 58 and 31% in the intensive lifestyle and metformin-treated groups, respectively, compared with the placebo-treated group (1).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Abstract
What the sources say
- Not checked — no full text of the sourcecites [1] The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393–403,2002 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These findings are compatible, with lifestyle having the greatest effect to preserve -cell function and it being the more effective intervention to reduce the rate of development of diabetes.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
hedgeddirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Finally, a decrease in -cell function would be characterized by a shift to the left of or below the curve.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus, it would appear that -cell function was unchanged in the lifestyle intervention group while declining in the control group.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
hedged- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Ninety-five percent of participants completed their first annual visit.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Table 1 presents baseline characteristics by treatment group.
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
In the paper
“This hyperbolic relationship has previously been described when more direct measures of insulin secretion and sensitivity were used (29).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [29] Kahn SE, Prigeon RL, McCulloch DK, Boyko EJ, Bergman RN, Schwartz MW, Neifing JL, Ward WK, Beard JC, Palmer JP, Porte D Jr: Quantification of the relationship between insulin sensitivity and B-cell function in human subjects: evidence for a hyperbolic function. Diabetes 42:1663–1672,1993 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Lifestyle intervention and, to a lesser extent, metformin enhanced -cell function and improved insulin sensitivity, leading to a reduced risk for developing diabetes.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The baseline relationship between insulin secretion and insulin sensitivity is the same across treatment groups.
- Rests on an assumption: The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Thus it appears that whereas change in body weight was a strong predictor of the risk of developing diabetes in the DPP, the interventions probably had differential effects on other variables or direct effects in the liver or muscle even after accounting for insulin secretion.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
hedgedconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
In the paper
“Similar findings of the effect of lifestyle intervention have been reported for the Finnish Diabetes Prevention Study (30).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [30] Uusitupa M, Lindi V, Louheranta A, Salopuro T, Lindström J, Tuomilehto J, Finnish Diabetes Prevention Study Group: Long-term improvement in insulin sensitivity by changing lifestyles of people with impaired glucose tolerance: 4-year results from the Finnish Diabetes Prevention Study. Diabetes 52:2532–2538,2003 source
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but whereas the absolute response declined, this decrease was not as large as might be expected from the concomitant change in insulin sensitivity and therefore can be interpreted as improved secretion relative to sensitivity.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > Changes in insulin secretion and sensitivity.
plaincorrelational- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“this process is never complete so that not all proinsulin molecules are cleaved, resulting in a small quantity of proinsulin being secreted along with insulin and C-peptide (36 -38).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [36] Kitabchi AE: Proinsulin and C-peptide a review. Metabolism 26:547–587,1977 source
- Not checked — no full text of the sourcecites [37] Mykkanen L, Haffner SM, Hales CN, Ronnemaa T, Laakso M: The relation of proinsulin, insulin, and proinsulin-to-insulin ratio to insulin sensitivity and acute insulin response in normoglycemic subjects. Diabetes 46:1990–1995,1997 source
- Not checked — no full text of the sourcecites [38] Reaven GM, Chen Y-DI, Hollenbeck CB, Sheu WHH, Ostrega D, Polonsky KS: Plasma insulin, C-peptide, and proinsulin concentrations in obese and nonobese individuals with varying degrees of glucose tolerance. J Clin Endocrinol Metab 76:44–48,1993 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The effect of metformin and intensive lifestyle in reducing the incidence of diabetes is related in part to their ability to shift the relationship between insulin sensitivity and insulin secretion in a direction compatible with an improvement in -cell function, with lifestyle being more effective in doing so.”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
plainconditional- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
It may state two separate claims as one.
- Rests on an assumption: The baseline relationship between insulin secretion and insulin sensitivity is the same across treatment groups.
- Rests on an assumption: The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
In the paper
“production of insulin is dependent on the proteolytic processing in the -cell secretory granule of proinsulin to insulin and C-peptide (35).”
§ Role of Insulin Secretion and Sensitivity in the Evolution of Type 2 Diabetes in the Diabetes Prevention Program Effects of Lifestyle Intervention and Metformin The Diabetes Prevention Program Research Group* > DISCUSSION
What the sources say
- Not checked — no full text of the sourcecites [35] Duckworth WC, Kitabchi AE, Heinemann M: Direct measurement of plasma proinsulin in normal and diabetic subjects. Am J Med 53:418–427,1972 source
plaindirect- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: fails — The paper’s conclusions may not depend on it.
- Based: passes — The paper gives a reason why it holds.
Probably not a substantial claim. The paper’s conclusions may not depend on it.
The authors state this as an assumption.
Hazard ratios were constant over time.
“Hazard ratios were assumed to be constant over time.”
The paper relies on this without support.
Deterioration of either insulin sensitivity or insulin secretion is critical in determining the progression of hyperglycemia.
“Although the relative importance of decreased insulin sensitivity and insulin secretion in the pathogenesis of type 2 diabetes has been debated, it is generally accepted that deterioration of either or both is critical in determining the progression of hyperglycemia.”
The paper relies on this without support.
Insulin resistance and β-cell dysfunction are central characteristics of type 2 diabetes, impaired fasting glycemia, and impaired glucose tolerance.
“Insulin resistance and -cell dysfunction are two well-established characteristics of type 2 diabetes, impaired fasting glycemia, and impaired glucose tolerance (IGT).”
The paper relies on this without support.
The baseline relationship between insulin secretion and insulin sensitivity is the same across treatment groups.
“The curve represents the regression line of the logarithm of estimated insulin secretion as a linear function of the logarithm of estimated insulin sensitivity for all participants at baseline.”
The paper relies on this without support.
The three scenarios (no change, improvement, decrease in β-cell function) exhaustively characterize possible changes in the insulin secretion-sensitivity relationship.
“changes in insulin secretion may reflect one of three scenarios regarding -cell function.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the Diabetes Prevention Program (DPP), greater baseline β-cell function and insulin sensitivity contributed independently to the restoration of NGT following lifestyle changes ( 65 , 66 ).”
From β-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and Prospects for Prevention and Treatment (2014) · cites this paper as [65]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Indeed, higher diabetes incidence in all treatment groups was found among individuals with lower measures of insulin secretory response at baseline in the DPP (22).”
From Increased genetic risk for β-cell failure is associated with β-cell function decline in people with prediabetes (2024) · cites this paper as [22]
In the citing paper
“Successful lifestyle interventions seem to improve insulin sensitivity and β-cell function.92,93”
From Prediabetes: a high-risk state for diabetes development (2012) · cites this paper as [93]
In the citing paper
“Since insulin resistance could increase the risk of AD through both cerebrovascular and Aβ related mechanisms [23]”
From Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial (2016) · cites this paper as [23]
In the citing paper
“Large intervention studies with lifestyle interventions and drugs like metformin have shown that it is feasible to decrease hyperinsulinemia and the risk of diabetes (The Diabetes Prevention Program Research, 2005) and is possible that these interventions could extend to decreasing the risk of Alzheimer’s disease.”
From Adiposity, hyperinsulinemia, diabetes and Alzheimer's disease (2008) · cites this paper as The Diabetes Prevention Program Research, 2005
In the citing paper
“Studies showing that metformin (MET) not only reduces insulin levels (11), inflammation and thrombosis (12), and the risk of the metabolic syndrome (13), but also improves insulin sensitivity (11) suggests its potential to exert protective effects on cognitive function.”
From Type 2 Diabetes and Antidiabetic Medications in Relation to Dementia Diagnosis (2014) · cites this paper as [11]
In the citing paper
“The putative mechanisms of MET's positive effects include (i) reducing insulin levels and improving insulin sensitivity (11), (ii) reducing inflammation (11), and (iii) reducing the risk of metabolic syndrome (25).”
From Type 2 Diabetes and Antidiabetic Medications in Relation to Dementia Diagnosis (2014) · cites this paper as [11]
Citations
Cites
Regression Models and Life-Tables
Cox, D. R. (1972) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1972.tb00899.x · Cited by 39,793
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Toprak, Ö., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney & Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,772
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 1×
“Finally, the DPP findings are also consistent with a recently reported study that demonstrated that a weight loss intervention in older individuals was associated with improved insulin sensitivity together with a relative preservation of the insulin response reflective of improved β-cell function (31) and provide a pl…”
ResultReport of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus* (2002) · Diabetes Care · doi:10.2337/diacare.25.2007.s5 · Cited by 10,325
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus (1997) · Diabetes Care · doi:10.2337/diacare.20.7.1183 · Cited by 6,220
Pan, X.-R., Li, G.-W., Hu, Y.-H., Wang, J.-X., Yang, W.-Y., An, Z.-X., Hu, Z.-X., Juan-Lin, Xiao, J.-Z., Cao, H.-B., et al. (1997) · Diabetes Care · doi:10.2337/diacare.20.4.537 · Cited by 4,320
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Kahn, S. E., Prigeon, R. L., McCulloch, D. K., Boyko, E. J., Bergman, R. N., Schwartz, M. W., Neifing, J. L., Ward, W. K., Beard, J. C., & Palmer, J. P. (1993) · Diabetes · doi:10.2337/diab.42.11.1663 · Cited by 1,405
Cited by
Sorted by citations
Items 101–200 of 443
Effects of intermittent fasting on cognitive health and Alzheimer’s disease
Elias, A., Padinjakara, N., & Lautenschlager, N. T. (2023) · Nutrition Reviews · doi:10.1093/nutrit/nuad021 · Cited by 85
Monti, L. D., Setola, E., Lucotti, P., Marrocco-Trischitta, M. M., Comola, M., Galluccio, E., Poggi, A. D., Mammì, S., Catapano, A. L., Comı, G., et al. (2012) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01615.x · Cited by 79
“However, by using a proxy measurement of β-cell function, proinsulin/c-peptide ratio, IGI/HOMA-IR, that have been extensively validated and used in previous studies including the Diabetes Prevention Program [38], the GENNID [35], and the DREAM [36] studies, we are able to suggest at least a maintenance of sufficient i…”
ResultInfluentialRetnakaran, R. R., Qi, Y., Sermer, M., Connelly, P. W., Zinman, B., & Hanley, A. J. (2008) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03393.x · Cited by 70
Pretransplant Risk Score for New-Onset Diabetes After Kidney Transplantation
Chakkera, H. A., Weil, E. J., Swanson, C. M., Dueck, A. C., Heilman, R. L., Reddy, K. S., Hamawi, K., Khamash, H. A., Moss, A. A., Mulligan, D. C., et al. (2011) · Diabetes Care · doi:10.2337/dc11-0752 · Cited by 71
Madsen, K. S., Chi, Y., Metzendorf, M.-I., Richter, B., & Hemmingsen, B. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd008558.pub2 · Cited by 70
for the ACT NOW Study Group, DeFronzo, R. A., Banerji, M. A., Bray, G. A., Buchanan, T. A., Clément, S., Henry, R. R., Kitabchi, A. E., Mudaliar, S. R. D., Musi, N., et al. (2009) · Diabetologia · doi:10.1007/s00125-009-1614-2 · Cited by 74
Jagannathan, R., Sevick, M. A., Li, H., Fink, D. A., Dankner, R. S., Chetrit, A., Roth, J., & Bergman, M. (2015) · Endocrine · doi:10.1007/s12020-015-0746-z · Cited by 68
Chng, C. L., Lim, A. Y., Tan, H. C., Kovalik, J., Tham, K. W., Bee, Y. M., Lim, W., Acharyya, S., Lai, O. F., Chong, S. C., et al. (2016) · Thyroid · doi:10.1089/thy.2015.0602 · Cited by 69
Measures of insulin sensitivity.
Bloomgarden, Z. (2006) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2006.06.007 · Cited by 65
Menopause and risk of diabetes in the Diabetes Prevention Program
Kim, C., Edelstein, S. L., Crandall, J. P., Dabelea, D., Kitabchi, A. E., Hamman, R. F., Montez, M. G., Perreault, L., Foulkes, M. A., & Barrett-Connor, E. L. (2011) · Menopause The Journal of The North American Menopause Society · doi:10.1097/gme.0b013e31820f62d0 · Cited by 68
Targeting the Consequences of the Metabolic Syndrome in the Diabetes Prevention Program
Goldberg, R. B., & Mather, K. J. (2012) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.111.241893 · Cited by 67
Initial Combination Therapy for Type 2 Diabetes Mellitus: Is It Ready for Prime Time?
Zinman, B. (2010) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.003 · Cited by 66
Nutritional guidelines for the management of insulin resistance
Muscogiuri, G., Barrea, L., Caprio, M., Ceriani, F., Chavez, A. O., El Ghoch, M., Frias-Toral, E., Mehta, R. J., Mendez, V., Paschou, S. A., et al. (2022) · Critical Reviews in Food Science and Nutrition · doi:10.1080/10408398.2021.1908223 · Cited by 63
Snehalatha, C., Mary, S., Selvam, S., Sathish Kumar, C. K., Shetty, S. B. A., Nanditha, A., & Ramachandran, A. (2009) · Diabetes Care · doi:10.2337/dc09-0676 · Cited by 64
Nutritional strategies to attenuate postprandial glycemic response
Pasmans, K., Meex, R. C. R., van Loon, L. J. C., & Blaak, E. E. (2022) · Obesity Reviews · doi:10.1111/obr.13486 · Cited by 75
The β Cell in Diabetes: Integrating Biomarkers With Functional Measures
Kahn, S. E., Chen, Y., Esser, N., Taylor, A. J., van Raalte, D. H., Zraika, S., & Verchere, C. B. (2021) · Endocrine Reviews · doi:10.1210/endrev/bnab021 · Cited by 75
Mather, K. J., KIM, C., Christophi, C., Aroda, V. R., Knowler, W. C., EDELSTEIN, S., Florez, J. C., Labrie, F., Kahn, S. E., Goldberg, R. B., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-2328 · Cited by 61
Alcohol consumption and diabetes risk in the Diabetes Prevention Program
Crandall, J. P., Polsky, S., Howard, A. A., Perreault, L., Bray, G. A., Barrett-Connor, E. L., Brown-Friday, J., Whittington, T., Foo, S. T., Ma, Y., et al. (2009) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.2008.27382 · Cited by 60
Goals of Treatment for Type 2 Diabetes
Marchetti, P., Lupi, R., Guerra, S. D., Bugliani, M., D’Aleo, V., Occhipinti, M., Boggi, U., Marselli, L., & Masini, M. (2009) · Diabetes Care · doi:10.2337/dc09-s306 · Cited by 62
van Raalte, D. H., & Verchere, C. B. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12935 · Cited by 63
An examination of β‐cell function measures and their potential use for estimating β‐cell mass
Kahn, S. E., Carr, D. B., Faulenbach, M. V., & Utzschneider, K. M. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00945.x · Cited by 59
Hemmingsen, B., Sonne, D. P., Metzendorf, M., & Richter, B. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012151.pub2 · Cited by 76
Andújar-Plata, P., Pi-Sunyer, X., & Laferrère, B. (2011) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2011.09.022 · Cited by 59
Interventions to Preserve Beta-Cell Function in the Management and Prevention of Type 2 Diabetes
Page, K. A., & Reisman, T. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0363-2 · Cited by 62
Masharani, U. B., Maddux, B. A., Li, X., Sakkas, G. K., Mulligan, K. M., Schambelan, M., Goldfine, I. D., & YOUNGREN, J. F. (2011) · PLoS ONE · doi:10.1371/journal.pone.0019878 · Cited by 62
“cardiovascular disease and related disorders [1,2].”
β-Cell preservation with thiazolidinediones
Campbell, I. W., & Mariz, S. (2006) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2006.08.015 · Cited by 57
Guess, N. D. (2018) · Nutrients · doi:10.3390/nu10091245 · Cited by 64
Metformin therapy and cognitive dysfunction in patients with type 2 diabetes
Zhang, Q., Li, W., Liu, Z., Zhang, H., Ba, Y., & Zhang, R. (2020) · Medicine · doi:10.1097/md.0000000000019378 · Cited by 63
“Studies have shown that metformin reduces insulin levels,([34]) improves inflammation and reduces thrombosis,([35]) reducing the risk of metabolic syndrome.”
Vinik, A. I. (2007) · Clinical Therapeutics · doi:10.1016/j.clinthera.2007.07.005 · Cited by 57
Lifestyle intervention to prevent diabetes: intensive AND cost effective
Wylie‐Rosett, J., Herman, W. H., & Goldberg, R. B. (2006) · Current Opinion in Lipidology · doi:10.1097/01.mol.0000203890.27267.eb · Cited by 57
Imamura, F., Mukamal, K. J., Meigs, J. B., Luchsinger, J. A., Ix, J. H., Siscovick, D. S., & Mozaffarian, D. (2013) · American Journal of Epidemiology · doi:10.1093/aje/kws440 · Cited by 58
Lamont, B. J., Waters, M. F., & Andrikopoulos, S. (2016) · Nutrition and Diabetes · doi:10.1038/nutd.2016.2 · Cited by 58
Plourde, C., Grenier–Larouche, T., Caron‐Dorval, D., Biron, S., Marceau, S., Lebel, S., Biertho, L. D., Tchernof, A., Richard, D., & Carpentier, A. C. (2014) · Obesity · doi:10.1002/oby.20771 · Cited by 55
“Assessment of b-cell function using determination of DI after an oral challenge has been well validated in prospective studies (30,31).”
MethodResultMetabolism and Breast Cancer Risk: Frontiers in Research and Practice
Patterson, R. E., Rock, C. L., Kerr, J., Natarajan, L., Marshall, S. J., Pakiz, B., & Cadmus‐Bertram, L. (2012) · Journal of the Academy of Nutrition and Dietetics · doi:10.1016/j.jand.2012.08.015 · Cited by 54
Goldberg, R. B., Temprosa, M. G., Mather, K. J., Orchard, T. J., Kitabchi, A. E., & Watson, K. E. (2014) · Diabetes Care · doi:10.2337/dc13-2471 · Cited by 55
Novel approaches to restore beta cell function in prediabetes and type 2 diabetes
Salunkhe, V. A., Veluthakal, R., Kahn, S. E., & Thurmond, D. C. (2018) · Diabetologia · doi:10.1007/s00125-018-4658-3 · Cited by 63
Espinoza, S. E., Musi, N., Wang, C.-P., Michalek, J. E., Orsak, B., Romo, T. Q., Powers, B., Conde, A., Moris, M., Bair‐Kelps, D., et al. (2019) · The Journals of Gerontology Series A · doi:10.1093/gerona/glz078 · Cited by 51
Continuous ketone monitoring: Exciting implications for clinical practice
Kong, Y. W., Morrison, D., Lu, J., Lee, M. H., Jenkins, A. J., & O'Neal, D. N. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15921 · Cited by 53
Gómez-Díaz, R. A., Talavera, J. O., Canché-Pool, E. B., Ortiz-Navarrete, V. F., Solórzano‐Santos, F., Mondragón-González, R., Valladares‐Salgado, A., Cruz, M., Aguilar-Salinas, C. A., & Wacher, N. H. (2012) · Metabolism · doi:10.1016/j.metabol.2012.02.003 · Cited by 53
Diabetes: 1 and 2, or one and the same? Progress with the accelerator hypothesis
Wilkin, T. J. (2008) · Pediatric Diabetes · doi:10.1111/j.1399-5448.2007.00343.x · Cited by 48
de Mello, V. D., Lindström, J., Eriksson, J. G., Ilanne‐Parikka, P., Keinanen-Kiukaanniemi, S. M., Sundvall, J., Laakso, M., Tuomilehto, J. O., & Uusitupa, M. I. J. (2011) · Diabetes Care · doi:10.2337/dc11-1272 · Cited by 50
Khan, H. A., Sobki, S. H., Ekhzaimy, A. A., Khan, I., & Almusawi, M. A. (2018) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2018.05.027 · Cited by 49
“Thus, a timely identification of IR in non-diabetic population is of a great importance in a community-based strategy to reduce the upcoming prevalence of T2DM, keeping in mind that interventional studies have demonstrated that preservation of b-cell function decreases the transformation of pre-diabetes to diabetes (K…”
BackgroundKilpeläinen, T. O., Lakka, T. A., Laaksonen, D. E., Laukkanen, O., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Aunola, S., Ilanne‐Parikka, P., et al. (2007) · Physiological Genomics · doi:10.1152/physiolgenomics.00036.2007 · Cited by 49
Type 2 Diabetes and Cognitive Compromise
Kravitz, E., Schmeidler, J., & Beeri, M. S. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.05.009 · Cited by 49
Somineni, R. P., Boivin, G. P., & Elased, K. M. (2014) · Journal of Endocrinology · doi:10.1530/joe-13-0532 · Cited by 48
“…manifest progressive deterioration of both insulin action and insulin secretion (Weyer et al. 1999) and it has been suggested that interventions should target both insulin abnormalities to prevent diabetes or to achieve maximal therapeutic benefits (Weyer et al. 1999, Kitabchi et al. 2005).”
Factors Associated with Beta-Cell Dysfunction in Type 2 Diabetes: The BETADECLINE Study
Russo, G. T., Giorda, C. B., Cercone, S., Nicolucci, A., Cucinotta, D., & on behalf of BetaDecline Study Group (2014) · PLoS ONE · doi:10.1371/journal.pone.0109702 · Cited by 47
Glucose Intolerance after a Recent History of Gestational Diabetes Based on the 2013 WHO Criteria
Benhalima, K., Jegers, K., Devlieger, R., Verhaeghe, J., & Mathieu, C. (2016) · PLOS ONE · doi:10.1371/journal.pone.0157272 · Cited by 45
Psychosocial and behavioral interventions for chronic medical conditions
Fekete, E. M., Antoni, M. H., & Schneiderman, N. (2007) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e3280147724 · Cited by 44
Long-term effects of chitosan oligosaccharide in streptozotocin-induced diabetic rats
Kim, J. N., Chang, I. Y., Kim, H. I., & Yoon, S. P. (2009) · Islets · doi:10.4161/isl.1.2.9143 · Cited by 44
Satoh, H., Nguyen, M. T., Kudoh, A., & Watanabe, T. (2013) · Nutrition and Diabetes · doi:10.1038/nutd.2013.11 · Cited by 44
Retnakaran, R. R., Qi, Y., Sermer, M., Connelly, P. W., Hanley, A. J., & Zinman, B. (2009) · Clinical Endocrinology · doi:10.1111/j.1365-2265.2008.03460.x · Cited by 42
The effect of metformin on cognitive function: A systematic review and meta-analysis
Tabatabaei‐Malazy, O., Bandarian, F., Qorbani, M., Mohseni, S., Mirsadeghi, S., Peimani, M., & Larijani, B. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211057304 · Cited by 43
Benhalima, K., Crombrugge, P. V., Verhaeghe, J., Vandeginste, S., Verlaenen, H., Vercammen, C., Dufraimont, E., Block, C. E. M. D., Jacquemyn, Y., Mekahli, F., et al. (2014) · BMC Pregnancy and Childbirth · doi:10.1186/1471-2393-14-226 · Cited by 44
Hivert, M.-F., Christophi, C. A., Franks, P. W., Jablonski, K. A., Ehrmann, D. A., Kahn, S. E., Horton, E. S., Pollin, T. I., Mather, K. J., Perreault, L., et al. (2016) · Diabetes · doi:10.2337/db15-0950 · Cited by 38
Henderson, D. C., Fan, X., Sharma, B., Copeland, P. M., Borba, C. P. C., Boxill, R., Freudenreich, O., Cather, C., Evins, A. E., & GOFF, D. C. (2009) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2008.01325.x · Cited by 39
Lascar, N., Kennedy, A., Jackson, N., Daley, A., Dowswell, G., Thompson, D., Stokes, K., Greenfield, S., HOLDER, R. L., Andrews, R. C., et al. (2013) · Trials · doi:10.1186/1745-6215-14-180 · Cited by 38
Peña, A., Olson, M. L., Hooker, E., Ayers, S. L., Castro, F. G., Patrick, D. L., CORRAL, L., Lish, E., Knowler, W. C., & Shaibi, G. Q. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.31196 · Cited by 42
Meng, W., Zhang, C., Zhang, Q., Song, X., Lin, H., Zhang, D., Zhang, Y., Zhu, Z., Wu, S., Liu, Y., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0049875 · Cited by 36
Damelin, L. H., Jivan, R., Veale, R. B., Rousseau, A. L., & Mavri‐Damelin, D. (2014) · BMC Cancer · doi:10.1186/1471-2407-14-314 · Cited by 38
Knowler, W. C., Doherty, L., Edelstein, S. L., Bennett, P. H., Dabelea, D., Hoskin, M., Kahn, S. E., Kalyani, R. R., Kim, C., Pi-Sunyer, F. X., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00022-1 · Cited by 39
Zhang, C.-Y., Sun, A., Zhang, S., Wu, C., Fu, M., Xia, G., Wang, K., Zou, Y., & Ge, J. (2010) · Annals of Medicine · doi:10.3109/07853891003796752 · Cited by 38
“Previous studies showed that metformin was an agent related with less weight-gain in patients with type 2 diabetes (23,24).”
ResultXiang, A. H., Trigo, E., Martinez, M., Katkhouda, N., Beale, E., Wang, X., Wu, J., Chow, T., Montgomery, C., Nayak, K. S., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1662 · Cited by 37
Vianna, R. M. J., Brault, A., Martineau, L. C., Couture, R., Arnason, J. T., & Haddad, P. S. (2009) · Evidence-based Complementary and Alternative Medicine · doi:10.1093/ecam/nep158 · Cited by 38
An endocrine perspective of nonalcoholic fatty liver disease (NAFLD)
Lomonaco, R., Chen, J., & Cusi, K. J. (2011) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018811419157 · Cited by 37
Schmid, V., Wagner, R. J., Sailer, C., Fritsche, L., Kantartzis, K., Peter, A., Heni, M., Häring, H., Stefan, N., & Fritsche, A. (2017) · Diabetologia · doi:10.1007/s00125-017-4407-z · Cited by 37
Glucoregulatory Physiology in Subjects with Low-Normal, High-Normal, or Impaired Fasting Glucose
Dagogo-Jack, S. E., Askari, H., & Tykodi, G. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1348 · Cited by 40
TCF7L2 Polymorphism, Weight Loss and Proinsulin∶Insulin Ratio in the Diabetes Prevention Program
McCaffery, J. M., Jablonski, K. A., Franks, P. W., Dagogo-Jack, S. E., Wing, R. R., Knowler, W. C., Delahanty, L. M., Dabelea, D., Hamman, R. F., Shuldiner, A. R., et al. (2011) · PLoS ONE · doi:10.1371/journal.pone.0021518 · Cited by 35
“However, the persistence of differences in proinsulin:insulin ratios across genotypic groups at TCF7L2 rs7903146, despite interventions shown to significantly improve insulin sensitivity [23], raises the possibility that this defect may be caused by a specific effect of TCF7L2 on proinsulin processing, b-cell prolifer…”
BackgroundPollin, T. I., Isakova, T., Jablonski, K. A., de Bakker, P. I. W., Taylor, A., McAteer, J. B., Pan, Q., Horton, E. S., Delahanty, L. M., Altshuler, D., et al. (2012) · PLoS Genetics · doi:10.1371/journal.pgen.1002895 · Cited by 35
“The effects of the DPP interventions on 1 yr changes in weight [14], insulin secretion [13], beta-cell function [13], and lipid traits [29] are reported in detail elsewhere.”
The Role of β‐Cell Dysfunction in the Cardiometabolic Syndrome
Lastra, G., Manrique, C. M., & Hayden, M. R. (2006) · Journal of the CardioMetabolic Syndrome · doi:10.1111/j.0197-3118.2006.05458.x · Cited by 38
Ramachandran, A., & Snehalatha, C. (2011) · Medical Clinics of North America · doi:10.1016/j.mcna.2010.11.006 · Cited by 36
Kitta, Y., Nakamura, T., Uematsu, M., Sugamata, W., Deyama, J., Fujioka, D., Saitō, Y., Kawabata, K., Obata, J., & Kugiyama, K. (2013) · Journal of Cardiology · doi:10.1016/j.jjcc.2013.05.006 · Cited by 34
Diet and Metabolic Syndrome: An Overview
Keane, D., Kelly, S., Healy, N. P., McArdle, M. A., Holohan, K., & Roche, H. M. (2014) · Current Vascular Pharmacology · doi:10.2174/15701611113116660173 · Cited by 36
Bauhinia forficata in the treatment of diabetes mellitus: a patent review.
de Souza, B. V. C., Moreira-Araújo, R. S. D. R., Silva, O. A., Faustino, L. C., Gonçalves, M. F. B., dos Santos, M. L., Souza, G. R., Rocha, L. D. M., Cardoso, M. L. S., & Nunes, L. C. C. (2018) · PubMed · doi:10.1080/13543776.2018.1409208 · Cited by 34
Primary prevention of Type 2 diabetes in South Asians — challenges and the way forward
Ambady, R., Snehalatha, C., Shetty, A. S., & Nanditha, A. (2012) · Diabetic Medicine · doi:10.1111/j.1464-5491.2012.03753.x · Cited by 34
Michishita, R., Shono, N., Kasahara, T., & Tsuruta, T. (2008) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2008.08.013 · Cited by 34
Metformina e AMPK: um antigo fármaco e uma nova enzima no contexto da síndrome metabólica
Santomauro Jún, A. C., Ugolini, M. R., Santomauro, A. T., & Souto, R. P. D. (2008) · Arquivos Brasileiros de Endocrinologia & Metabologia · doi:10.1590/s0004-27302008000100017 · Cited by 33
Lexis, C. P. H., van der Horst‐Schrivers, A. N. A., Lipšic, E., Valente, M. A. E., Kobold, A. C. M., de Boer, R. A., van Veldhuisen, D. J., van der Harst, P., & van der Horst, I. C. C. (2015) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2015-000090 · Cited by 34
Isop, L. M., Neculau, A. E., Necula, R. D., Kakucs, C., Moga, M., & Dima, L. (2023) · Pharmaceuticals · doi:10.3390/ph16121714 · Cited by 36
Zheng, L., Linarelli, L. E., Brooke, J., Smith, C., Wall, S. S., Greenawald, M. H., Seidel, R. W., Estabrooks, P. A., Almeida, F. A., & Cheng, Z. (2016) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2016/5290638 · Cited by 35
Detecting people at high risk of type 2 diabetes- How do we find them and who should be treated?
Kong, A. P. S., Luk, A. O. Y., & Chan, J. C. N. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.003 · Cited by 36
Prevention of type 2 Diabetes Mellitus: Potential of pharmacological agents
Samson, S. L., & Garber, A. J. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.005 · Cited by 37
“More than half of the effect of metfo rmin was explained by weight loss, which improved insulin sensitivity [11].”
BackgroundMitri, J., Nelson, J., Ruthazer, R., Garganta, C. L., Nathan, D. M., Hu, F. B., Dawson-Hughes, B. F., & Pittas, A. G. (2014) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2013.293 · Cited by 34
Rattarasarn, C. (2006) · Acta Physiologica · doi:10.1111/j.1748-1716.2005.01521.x · Cited by 34
“…improve b-cell function (The Diabetes Prevention Program Research Group 2005a) and reduce circulating inflammatory markers associated with insulin resistance (The Diabetes Prevention Program Research Group 2005b) as well as delay the development of diabetes in several primary prevention studies.”
BackgroundHe, X., Wu, D., Hu, C., Xu, T., Liu, Y., Liu, C., Xu, B., & Tang, W. (2018) · Thyroid · doi:10.1089/thy.2017.0707 · Cited by 35
Serbis, A., Giapros, V. I., Tsamis, K. I., Balomenou, F., Galli‐Τsinopoulou, A., & Siomou, E. C. (2023) · Nutrients · doi:10.3390/nu15092217 · Cited by 42
“clinical centers, it was shown that, in a high-risk “prediabetic” population the presence of reduced insulin sensitivity together with decreased insulin secretion jointly increase the diabetes development risk over time [36].”
BackgroundManipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners
Shibib, L., Al-Qaisi, M., Guess, N. D., Miras, A. D., Greenwald, S. E., Pelling, M., & Ahmed, A. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s458894 · Cited by 41
Goldberg, R. B., Bray, G. A., Marcovina, S. M., Mather, K. J., Orchard, T. J., Perreault, L., & Temprosa, M. G. (2018) · Diabetologia · doi:10.1007/s00125-018-4748-2 · Cited by 31
“Semi-annual measurements of weight, BP and fasting glucose and annual measurements of HDL-cholesterol, triacylglycerol and HbA1c, and glucose tolerance by OGTT, were performed.”
BackgroundMethodInfluentialEffect of genotype on success of lifestyle intervention in subjects at risk for type 2 diabetes
Weyrich, P., Stefan, N., Häring, H., Laakso, M., & Fritsche, A. (2006) · Journal of Molecular Medicine · doi:10.1007/s00109-006-0134-5 · Cited by 32
Persistence of improvement in insulin sensitivity following a dietary weight loss programme
McLaughlin, T., Schweitzer, P., Carter, S., Yen, C. ‐., Lamendola, C. A., Abbasi, F., & Reaven, G. M. (2008) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2008.00877.x · Cited by 31
Prediabetes: To treat or not to treat?
Moutzouri, E., Tsimihodimos, V., Rizos, E. C., & Elisaf, M. (2011) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2011.10.007 · Cited by 31
Leukocyte-related parameters in older adults with metabolic syndrome
Yang, X., Tian, S., Ma, Q., Sun, H., Xu, Y., & Pan, C. (2020) · Endocrine · doi:10.1007/s12020-020-02243-2 · Cited by 30
Cardiometabolic Risk in Chinese Women with Prior Gestational Diabetes: A 15-Year Follow-Up Study
Tam, W. H., Ronald, C. W., Yang, X., Ko, G. T.-C., Lao, T. T.-H., Chan, M. H. M., Lam, C. W.-K., Cockram, C. S., & Chan, J. C. N. (2011) · Gynecologic and Obstetric Investigation · doi:10.1159/000329339 · Cited by 29
Implementation of a lifestyle program in primary care by nurse practitioners
Whittemore, R., Melkus, G. D., Alexander, N., Zibel, S., Visone, E., Muench, U., Magenheimer, E. A., & Wilborne, S. (2010) · Journal of the American Academy of Nurse Practitioners · doi:10.1111/j.1745-7599.2010.00562.x · Cited by 30
“Lifestyle changes of healthy eating and physical activity contribute to weight loss and improvement in IR, which have been shown to predict progression to T2D in at-risk adults (Kitabchi et al., 2005).”
BackgroundWorse Pancreatic -cell Function and Better Insulin Sensitivity in Older Chinese Without Diabetes
Xiao, J., Weng, J., Ji, L., Jia, W., Lu, J., Shan, Z., Liu, J., Tian, H., Ji, Q., Yang, Z., et al. (2013) · The Journals of Gerontology Series A · doi:10.1093/gerona/glt104 · Cited by 29
Gaetano, A. D., & Hardy, T. A. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222833 · Cited by 29
Retnakaran, R. R., Qi, Y., Harris, S. B., Hanley, A. J., & Zinman, B. (2011) · Diabetes Care · doi:10.2337/dc11-0046 · Cited by 28
“This waning insulin sensitization after the first year is similar to that which was observed with both metformin and lifestyle in the Diabetes Prevention Program (14).”
ResultShi, Y., Liu, W., Zhang, X., Su, W., Chen, N., Lu, S., Wang, L., Shi, X., Li, Z., & Yang, S. (2016) · Chinese Medical Journal · doi:10.4103/0366-6999.190676 · Cited by 28
Crandall, J. P., Dabelea, D., Knowler, W. C., Nathan, D. M., Temprosa, M., DPP Research Group, Bray, G. A., Gadde, K. M., Culbert, I. W., Arceneaux, J., et al. (2025) · Diabetes Care · doi:10.2337/dc25-0014 · Cited by 29
Changes in Albumin Excretion in the Diabetes Prevention Program
Diabetes Prevention Program Research Group (2009) · Diabetes Care · doi:10.2337/dc08-1400 · Cited by 26
Viskochil, R. H., Malin, S. K., Blankenship, J. M., & Braun, B. (2017) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00790.2016 · Cited by 29
“Up to 70% of individuals with prediabetes (fasting and/or postchallenge glucose concentrations above normal but below the range of frank T2D) are characterized by an inappropriate matching of insulin secretion and sensitivity (7), and without lifestyle or pharmacological intervention the transition from prediabetes to…”
BackgroundInfluential
Metadata
- Authors
- The Diabetes Prevention Program Research Group
- Affiliations
- George Washington University (US)
- Corresponding author
- The Diabetes Prevention Program Research Group
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2005-08-01
- Volume
- 54
- Issue
- 8
- Pages
- 2404-2414
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC1360738
- OpenAlex
- W11872906
- Semantic Scholar
- 325f16dd65ffe228accc202bdf7b70e715176447
- Cited by
- 446
- References
- 49
- Citations by year
- 2026: 12 · 2025: 9 · 2024: 16 · 2023: 19 · 2022: 14 · 2021: 19 · 2020: 19 · 2019: 18 · 2018: 22 · 2017: 17 · 2016: 26 · 2015: 24 · 2014: 26 · 2013: 17 · 2012: 31
- FWCI
- 16.99
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- American Diabetes Association
- Bristol-Myers Squibb
- National Institutes of Health
- Centers for Disease Control and Prevention
- National Institute on Aging
- National Institute of Diabetes and Digestive and Kidney Diseases (U01DK048489)
- National Institute of Child Health and Human Development
- National Center for Research Resources
- Office of Women's Health
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- type 2 diabetes prevention, insulin secretion, insulin sensitivity, insulin resistance, beta-cell dysfunction, impaired glucose tolerance, metformin, intensive lifestyle intervention, Diabetes Prevention Program, diabetes incidence, weight change
- MeSH terms
- Insulin Secretion, Adult, Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Fasting, Female, Glucose Tolerance Test, Humans, Hypoglycemic Agents, Insulin, Insulin Resistance, Islets of Langerhans, Life Style, Male, Metformin, Middle Aged, Placebos
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-11, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-11 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
